Home › Funds › Royalty Pharma Sub-Manager, LLC › BHVN
Royalty Pharma Sub-Manager, LLC position in BHVN
BIOHAVEN LTD · Health Care
Royalty Pharma Sub-Manager, LLC reported holding 2,936,507 shares of BHVN (BIOHAVEN LTD) in its Q3 2026 13F filing — a position valued at US$39.2M, representing 19.97% of its reported portfolio and ranking #3 among its reported holdings. Royalty Pharma Sub-Manager, LLC has disclosed BHVN holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Royalty Pharma Sub-Manager, LLC's BHVN position evolved
Royalty Pharma Sub-Manager, LLC first disclosed a stake in BHVN in Q4 2025 at 2,936,507 shares (US$33.2M). The position peaked in Q2 2026 at 2,936,507 shares, worth US$43.7M. Across 4 filings, Royalty Pharma Sub-Manager, LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 2,936,507 shares valued at US$39.2M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 2.94M | $33.15M | New |
| Q1 2026 | 2.94M | $24.84M | Hold |
| Q2 2026 | 2.94M | $43.70M | Hold |
| Q3 2026 | 2.94M | $39.20M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BHVN and 13F data
BHVN (BIOHAVEN LTD) is a Health Care company. 26 other funds we track also report a position in BHVN — the largest reported positions include MONTANOVA CAPITAL, LLC (US$153.1M), INFINITUM ASSET MANAGEMENT, LLC (US$93.0M), Cormorant Asset Management, LP (US$38.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BHVN
- MONTANOVA CAPITAL, LLC 10.29M sh · $153.07M · Q2 2026
- INFINITUM ASSET MANAGEMENT, LLC 6.25M sh · $93.00M · Q2 2026
- Cormorant Asset Management, LP 2.61M sh · $38.84M · Q2 2026
- Knoll Capital Management, LLC 2.35M sh · $35.01M · Q2 2026
- TCG Crossover Management, LLC 1.78M sh · $26.49M · Q2 2026
More on Royalty Pharma Sub-Manager, LLC
FAQ
How long has Royalty Pharma Sub-Manager, LLC held BHVN?
Royalty Pharma Sub-Manager, LLC has disclosed BHVN holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Royalty Pharma Sub-Manager, LLC's current position in BHVN?
As of Q3 2026, Royalty Pharma Sub-Manager, LLC holds 2.94M shares of BHVN (BIOHAVEN LTD), valued at $39.20M, representing 19.97% of its reported portfolio and ranking #3.
Has Royalty Pharma Sub-Manager, LLC been buying or selling BHVN?
In the latest 13F filing (Q3 2026), Royalty Pharma Sub-Manager, LLC held unchanged its position in BHVN. The position peaked in Q2 2026 at 2.94M shares.
Which other funds hold BHVN?
Other major institutional holders of BHVN include MONTANOVA CAPITAL, LLC, INFINITUM ASSET MANAGEMENT, LLC, Cormorant Asset Management, LP, among 26 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.